NRC (National Research Council). 2010. The prevention and treatment of missing data in clinical trials. Panel on handling missing data in clinical trials. Washington, DC: The National Academies Press.
Owens, D. K., K. N. Lohr, D. Atkins, J. R. Treadwell, J. T. Reston, E. B. Bass, S. Chang, and M. Helfand. 2010. AHRQ series paper 5: Grading the strength of a body of evidence when comparing medical interventions-Agency for Healthcare Research and Quality and the Effective Health-care Program. Journal of Clinical Epidemiology 63(5):513-523.
Oxford Dictionaries. 2011. Oxford English Dictionary online. Oxford University Press.
Parks, M. H. 2010. Memorandum from Mary Parks to Curtis Rosebraugh (dated August 19, 2010). Re: Recommendations on marketing status of Avandia (rosiglitazone maleate) and the required post-marketing trial, Thiazolidinedione Intervention and Vitamin D Evaluation (TIDE) following the July 13 and 14, 2010 Public Advisory Committee Meeting. Silver Spring, MD: US Food and Drug Administration.
Parmigiani, G. 2002. Modeling in medical decision making: A Bayesian approach (statistics in practice). New York: Wiley.
Peng, R. D., F. Dominici, and S. L. Zeger. 2006. Reproducible epidemiologic research. American Journal of Epidemiology 163(9):783-789.
PMA (Cochrane Prospective Meta-Analysis Methods Group). 2010. Welcome: The prospective meta-analysis methods group. http://pma.cochrane.org/ (accessed December 12, 2011).
Psaty, B. M., and D. S. Siscovick. 2010. Minimizing bias due to confounding by indication in comparative effectiveness research: The importance of restriction. JAMA 304(8):897-898.
Psaty, B. M., R. Boineau, L. H. Kuller, and R. V. Luepker. 1999. The potential costs of upcoding for heart failure in the United States. The American Journal of Cardiology 84(1):108-109.
Psaty, B. M., C. J. O’Donnell, V. Gudnason, K. L. Lunetta, A. R. Folsom, J. I. Rotter, A. G. Uitterlinden, T. B. Harris, J. C. M. Witteman, E. Boerwinkle, and (on behalf of the CHARGE Consortium). 2009. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. Circulation: Cardiovascular Genetics 2(1):73-80.
Reade, M., A. Delaney, M. Bailey, D. Harrison, D. Yealy, P. Jones, K. Rowan, R. Bellomo, and D. Angus. 2010. Prospective meta-analysis using individual patient data in intensive care medicine. Intensive Care Medicine 36(1):11-21.
Royall, R. M. 1997. Statistical evidence: A likelihood paradigm. London, UK: Chapman & Hall.
Saunders, K., K. Dunn, J. Merrill, M. Sullivan, C. Weisner, J. Braden, B. Psaty, and M. Von Korff. 2010. Relationship of opioid use and dosage levels to fractures in older chronic pain patients. Journal of General Internal Medicine 25(4):310-315.
Staffa, J. A., J. Chang, and L. Green. 2002. Cerivastatin and reports of fatal rhabdomyolysis. New England Journal of Medicine 346(7):539-540.
Talbot, J. C. C., and P. Walker. 2004. Stephens’ detection of new adverse drug reactions. 5th ed. West Sussex, England: John Wiley & Sons Ltd.
Temple, R., and S. S. Ellenberg. 2000. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Annals of Internal Medicine 133(6):455-463.
Ten Have, T. R., S. L. Normand, S. M. Marcus, C. H. Brown, P. Lavori, and N. Duan. 2008. Intent-to-treat vs. non-intent-to-treat analyses under treatment non-adherence in mental health randomized trials. Psychiatrics Annals 38(12):772-783.
Thomas, E. J., and L. A. Petersen. 2003. Measuring errors and adverse events in health care. Journal of General Internal Medicine 18(1):61-67.
Thompson, S. G., and S. J. Sharp. 1999. Explaining heterogeneity in meta-analysis: A comparison of methods. Statistics in Medicine 18:2693-2708.
Toh, S., and M. A. Hernán. 2008. Causal inference from longitudinal studies with baseline randomization. International Journal of Biostatistics 4(1):Article22.